Objective: To investigate the relevance of serum topiramate (TPM) levels (SL) monitoring in the clinical management of epileptic patients. Methods: Twenty-seven patients with different epileptic syndromes on TPM therapy were studied.
Introduction
The pharmacokinetic profile of TPM is characterized by a rapid and nearly complete absorption, unaffected by food, linear kinetics, no autoinduction, no active metabolites, low binding to plasma proteins, which limits its interaction potential, predominant renal elimination, long elimination half-life allowing b.i.d. dosing with or without hepatic-enzyme inducers. 1, 2 Pharmacokinetic interactions with other AEDs are limited to increased TPM plasma clearance in presence of hepatic enzyme inducers [e.g. phenytoin (PHT), carbamazepine (CBZ)]. TPM may also increase PHT serum levels (SL) in some patients. [2] [3] [4] [5] [6] It's well known that during valproate (VPA) cotherapy, a slight but statistically significant decrease in both TPM (15-17%) and VPA (11%) SL were observed. 2, 5, 30 On the contrary, in a more recent study, no significant influence of VPA on TPM SL was found. 6 Clinically relevant pharmacokinetic interactions between TPM and other new AEDs have not been reported, 2 in particular no significant impact with lamotrigine is known. 38 The most relevant interactions between TPM and not-antiepileptic drugs in literature are relative to oral contraceptive (with TPM dosages higher than 200 mg/die), digoxine, lithium, amitriptyline, propranolol, but effects are relatively modest. 28, 29, 37, 38 Higher mg per kg dosages may be necessary in children and infants because of increased TPM clearance rates. 2, [6] [7] [8] [9] [10] The relationship between TPM dose and efficacy has been well established from several clinical trials. [11] [12] [13] [14] [15] On the other hand, the relationship between TPM SL and clinical course has not been so widely investigated. Considerable overlap exists in TPM SL between responders and not responders 16 as between patients experiencing adverse effects and those who do not.
So, no recommendations for a therapeutic range of TPM SL can be derived from the studies till now reported except a recent randomized, concentration-controlled trial of TPM in refractory focal epilepsy. This trial indicates low-medium levels Clinical experience with topiramate dosing and serum levels in patients with epilepsy 87 (between 6 and 31 mmol/l) as the best concentration range related to efficacy and tolerability. 27 In the clinical experience here reported we evaluated prospectively a sample of epileptic patients who started treatment with TPM, in monotherapy or in add-on. The aim was to investigate the relationship between TPM SL and clinical course, other than the influence on dosage, age and comedication.
Patients and methods
Twenty-seven patients (16 males and 11 females; age range: 16 months-46 years, mean: 22 years) from Epilepsy Center of ''E. Medea'' Institute were treated with TPM. In one case TPM was used as mono-therapy. In another patient (number 11) TPM was initially added to CBZ and then, during follow-up, CBZ was gradually withdrawn. In this patient two TPM SL were obtained, before (i.e. bi-therapy with TPM and CBZ) and after CBZ withdrawal (TPM mono-therapy). Therefore in seven patients TPM was used in addition to another AED. In 19 patients TPM was associated with two or three AEDs. Clinical data of the patients are shown in Table 1 .
Four patients were also receiving not antiepileptic drugs (hormonal replacement, anti-inflammatories, antiarrhythmic, psycho-tropic, antispastic drugs). Nineteen patients had focal symptomatic epilepsy, two focal cryptogenic epilepsy, five symptomatic generalized epilepsy, including two with progressive myoclonus epilepsy (Unverricht-Lundborg disease) and one in whom epilepsy was undetermined whether focal or generalized.
Nineteen patients had second grade refractory epilepsy according to classification proposed by Perucca, 17 with persistence of seizures despite at least two adequate AEDs, used alone or in combination; furthermore, three patients had third grade refractory epilepsy. The study was approved by the Institutional Review Board and a written informed consent was obtained from the patients or their parents.
The initial dose of TPM was 0.5-1 mg/kg/day in the children (age <15 years) and 25 mg/day in the adults for 7-10 days. Dosage was then slowly titrated with 1-3 mg/kg/day or 25 mg/day at 7-10 days increments until efficacy or side effects occurred. Target dosage was 5 mg/kg/day in children and 100 mg/day in adults. Successively TPM dosages were eventually increased, if tolerated, with similar titration schedule, to a maximum dosage of 10 mg/kg/day in children and 600 mg/ day in adults. The titration was stopped in all cases where further seizure reduction did not occur.
We included patients whose clinical history and seizure frequency were well known and were followed in our Epilepsy Center from at least one year. Patients were clinically evaluated at the initial visit before administration of TPM. After 4-5 weeks when target dose was achieved, they were revaluated through medical examination, clinical laboratory tests and monitoring levels of AEDs (including TPM SL). Subsequently, these evaluations were repeated after 3 and 6 months, in the first year of TPM therapy.
A diary of seizure activity was kept by patients or their parents and examined at each visit. The average follow-up was 11 months (range: 2-36 months). Responders were considered those patients who achieved a !50% reduction in mean seizure frequency at follow-up visits compared with the baseline period. The quantitative determination of TPM in serum was measured by the IMMUNOFLUOR* TOPIRAMATE Assay System, a fluorescence polarization immunoassay (FPIA) with an Abbott TDX instrument. Each assay required at least 75 ml of serum or heparinized plasma; samples were collected in the morning before meal and drug assumption. Hemolyzed samples were not considered. Patient samples were stored at 2-8 8C for no longer than 24 h or directly frozen at À20 8C before carrying out biochemical analysis. TPM SL were recorded on the analyzer printout in mmol/l.
Statistical analysis was performed using t-test for two groups and analysis of variance (ANOVA) for more than two. Factors considered were clinical response, age and comedication with inducing and not inducing AEDs. All variables were related to both SL mean and the level to dose ratio (LDR). LDR is the ratio between TPM SL (mmol/l) and TPM dose per body weight (mg/kg), as defined by May. 6 The relationship with inducing and not inducing AEDs was first analyzed in all patients, then only in adults to avoid age as confounding factor. Furthermore, multiple regression analysis was performed using TPM SL and LDR as dependent variables and age, TPM dosage and inducing comedication as independent variables.
Results
We analyzed the TPM SL in 43 samples from 27 patients (11 patients had two or more samples). Eighteen patients received TPM associated with enzyme-inducing AEDs, eight with not enzyme-inducing AEDs. Five out of 18 cases with enzyme-inducing AEDs also received VPA. The mean steady state TPM dose was 3.9 mg/kg daily (range 0.7-10.9); the mean TPM SL was 13.43 mmol/l (range 1.47-34.27). Mean LDR value was 3.63 mmol/l/mg/kg. Fig. 1 shows the relationship between the TPM daily dosage and the corresponding SL in patients on TPM monotherapy and in those comedicated with enzyme-inducing (CBZ, PB, PHT) and not enzymeinducing AEDs. Although there is a good dosage to SL correspondence; there are still some important deviations depending on age and comedications.
The two children younger than 2 years received dosages higher than the mean (9 and 4.3 mg/kg/day, respectively) but had SL near (13.67 mmol/l) or lower (4.2 mmol/l) than the mean with a very low LDR (0.97 and 1.5 mmol/l/mg/kg, respectively). Furthermore, all children (age <15 years) had lower SL (mean 8 mmol/l) than the adults (mean 13.7 mmol/l); this trend, however, was not significant (t = 1.65; p = 0.11) (Fig. 2) .
The comedication with an enzyme-inducing AED was another factor able to reduce TPM SL and LDR. However, only the LDR reduction was significant (ttest = 2.81; p = 0.010) (Fig. 3) .
The mean LDR, calculated separately, was 5.3 mmol/l/mg/kg for patients with not inducing AEDs and 2.9 mmol/l/mg/kg for those with inducing-enzyme AEDs (2.5 when VPA was also associated). These differences, already significant by ANOVA (F = 3.9; p = 0.035), were much more significant (F = 11.1; p = 0.008) if only adults were considered (3.1 mmol/l/mg/kg with inducing AEDs, 2.5 with also VPA, and 7.3 with not inducing).
The treatment with an inducing comedication, by multiple regression analysis, turned out to be a factor able to reduce significantly LDR but not TPM SL. This result was obtained considering either adults only (Tables 2 and 3 ) or whole sample (in this case the adjusted R 2 was 0.45 for SL and 0.32 for LDR). Only two patients had SL on TPM monotherapy, so a statistical analysis was not performed on this group.
Efficacy
Four patients became seizure-free. All 4 cases received TPM dosages lower than the mean. Eleven Clinical experience with topiramate dosing and serum levels in patients with epilepsy 89 Figure 1 Relationship between daily TPM dosage and TPM SL in patients on TPM monotherapy and in those comedicated with enzyme inducing and not inducing AEDs. There is a good dosage to SL correspondence due to TMP linear kinetics.
Figure 2 TPM SL in adults versus children (age <15 years). All children had lower SL (mean 8 mmol/l) than the adults (mean 13.7 mmol/l); this trend, however, was not significant (t = 1.65; p = 0.11). patients had at least 50% seizure reduction. Four patients, even if not definable as responders because their seizure frequency did not decrease, showed a favorable effect: in fact they had no more drop-attacks. Their SL mean resulted significantly higher (23.7 mmol/l) than SL mean in seizure-free group (9.1 mmol/l) and inefficacy group (8.7 mmol/ l) by ANOVA (F = 4.52; p = 0.015). The patients with at least 50% seizure reduction had SL mean (12.8 mmol/l) middle between seizure-free group/ inefficacy group and the group with seizure intensity reduced, but this trend was not significant. In four patients efficacy could not be evaluated because of unsuccessful attempt to reduce associated AED in two cases (cases number [11] [12] [13] [14] [15] [16] [17] , and because of a short follow-up time in other two (cases number 20-21).
Adverse effects
None had seizure worsening. In one case TPM was tapered off because of inefficacy, TPM SL was 13.67 mmol/l (VPA associated). In other three patients TPM tapering was due to both adverse effects (sedation, drooling) and inefficacy (none with SL over the mean; more than two AEDs associated).
Repeated samples
Multiple samples were obtained from 11 patients and in 6 of them overlapping SL and LDR values were detected without changing therapy.
On the other hand, in the five remaining patients the LDR was unchanged in all cases except one, both before and after TPM and/or inducing AED dosages variations. That particular patient stopped CBZ and remained on TPM monotherapy, with LDR increasing. All these patients continued to have at least 50% seizure reduction.
Discussion
Our report, although is not a controlled trial, could be considered a first step to verify clinical utility of SL TPM monitoring in patients with different clinical characteristics, namely the type of epilepsy, the severity of seizure disorder and the type of concomitant medication.
The role and clinical impact of SL monitoring in AEDs management have been discussed for a long time. In particular, about new AEDs, on the one hand several authors affirm scanty utility of SL monitoring, [18] [19] [20] [21] on the other hand some studies show that also these drugs are characterized by several interactions. 6, 22, 23 Although therapeutic SL range of TPM has not been established yet to allow a routine monitoring, TPM SL may be useful in selected patients, such as those suspected of poor compliance and those in whom pharmacokinetic changes due to disease or comedication are expected. 24, 25 The wide interindividual variability in the serum concentrations at which therapeutic and toxic effects of these drugs are observed, does not necessarily imply that SL cannot be useful. Indeed, a marked pharmacodynamic variability has also been reported for all the older currently monitored anticonvulsants. 24 Even in the presence of marked interindividual pharmacodynamic variability, it is often possible to empirically determine the concentration at which each patient exhibits the best response, and apply that information in subsequent management. 24 We have considered total TPM SL and not free fraction because TPM reportedly binds in saturable manner to erythocytes but minimally to plasma proteins -around 15% of TPM is bound to plasma proteins [35] [36] [37] -so displacement effect, i.e. displacement of VPA binding sites, should not be relevant.
Our SL values are similar to those reported in the literature 26 by using the same methods with respect to patient's age and TPM dosages.
The analysis of our sample, even if small and heterogeneous, confirms a good relationship between TPM dosages and SL (by multiple regression analysis, an increase of 1 mg/kg induces an increase of 2.2 mmol/l, when adults were considered).
Nevertheless it also suggests some considerations. Childhood, because of increased drug clearance, and comedication with enzyme-inducers AEDs are important factors that reduce TPM SL and LDR, even if in our analysis a significant LDR reduction was observed only in presence of enzyme-inducers, probably due to small sample size. According to the literature, [2] [3] [4] [5] [6] 33, 38 the most relevant TPM SL variations are expected in case of TPM associated with inducing-AEDs (CBZ, PHT, PB). On the other hand, effect of coadministration of VPA is not univocally predictable in our study, depending upon the association with inducing-AEDs.
Regarding non-antiepileptic comedication, we have not found data in the literature about drugs administered to our four patients (namely thyroxine, risperidone, insulin, chloroquine, sotalol, dantrolene); only one study 38 reports data on the effect of TPM on risperidone and not vice versa.
About clinical impact of TPM SL, no direct relationship between SL and efficacy has been demonstrated in our experience, except that between higher SL and seizure intensity reduction. None of the patients who received TPM dosages higher than the target dose, with higher SL, achieved full seizure control.
However, also our data seem to indicate lowmedium levels as optimal ones, in accordance with the recent reported trial. 27 Our patients have not achieved TPM levels so high as 56 mmol/L 27 and this may explain the lower incidence of adverse events in our experience. Those of our patients who complained adverse effects showed SL below the mean value. Consistent with our results are the data reported by another study, 31 in which the authors show that, in patients treated with TPM plus AED inducers and not inducers, no consistent relation was observed between TPM plasma concentrations and adverse effects, mostly involving central nervous system, complained by 34% of patients.
All our patients with adverse effects were on polytherapy with other two or three AEDs. In particular, two of these patients were co-treated with VPA, therefore sedation reported in these cases could be a symptom of encephalopathy due to combination of TPM and VPA, as reported by Hamer et al. 32 However, unlike Hamer's report, in our cases ammonia concentrations were not elevated. Nevertheless, we cannot exclude a pharmacodynamic mechanism due to a direct toxicity of TPM in at risk patiens. 34 In conclusion, there seems not to be a direct relation between high TPM SL and seizure control neither between high TPM SL and adverse effects. However, there could be a greater probability to reduce seizure severity (in particular, to stop dropattacks) with high dosages and SL.
